Form
SCHEDULE 13G
Passive or exempt beneficial ownership filing.
ABG Management Ltd. - 04 Mar 2025 SCHEDULE 13G Report for Aadi Bioscience, Inc. Common Stock, par value $0.0001 per share (WHWK)
- Filing manager
- ABG Management Ltd.
- Reporting owner
- Fan Yu
- Beneficially owned shares
- 2,914,605 shares
- Large-stake signal
-
Ownership
6.3%Beneficial ownership of this reported class.
Shares
2,914,605 sharesShares beneficially owned as disclosed.
Event date
04 Mar 2025Date tied to the ownership event or amendment.
Accepted by SEC
10 Mar 2025EDGAR acceptance date.
How to read this large-stake filing
- Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
- Compare this filing with the holder history and issuer page before treating the percentage as a current position.
- Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
- Class ownership
- 6.3%
- Symbol
- WHWK
- Shares outstanding
- 46,263,571 shares
- SEC form
- SCHEDULE 13G
- Accepted by SEC
- 10 Mar 2025, 16:30:10 UTC
- Event date
- 04 Mar 2025
- Source filing
- View source filing
Ownership signal
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Subject security
Names, identifiers, and filing context for this profile.
2 source fields
Source evidence
Original filing metadata and source links for verification.
4 source fields
Key filing fact
ABG Management Ltd. disclosed 6.3% ownership in Aadi Bioscience, Inc. Common Stock, par value $0.0001 per share (WHWK) on 04 Mar 2025.
Key facts
- ABG Management Ltd. filed SCHEDULE 13G for Aadi Bioscience, Inc. Common Stock, par value $0.0001 per share (WHWK).
- Disclosed ownership: 6.3%.
- Date of event: 04 Mar 2025.
Change
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 10 Mar 2025, 16:30.
Research use
- This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
- Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.
Evidence
Backed by Schedule 13D/13G
View source filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Disclosed reporting parties (13)
Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares owned | Sole voting power | Shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| ABG Management Ltd. | 1.8% | 817,939 | 817,939 | 817,939 | By: /s/ Fan Yu | Fan Yu, Director | |
| Ally Bridge Group (NY) LLC | 1.8% | 817,939 | 817,939 | 817,939 | By: ABG Management Ltd., its managing member, By: /s/ Fan Yu | Fan Yu, Director | |
| Ally Bridge MedAlpha Master Fund L.P. | 1.8% | 817,939 | 817,939 | 817,939 | By: Ally Bridge Group (NY) LLC, its manager, By: ABG Management Ltd., its managing member, By: /s/ Fan Yu | Fan Yu, Director | |
| ABG Innovation Capital Partners III GP Limited | 0.1% | 26,666 | 26,666 | 26,666 | By: /s/ Fan Yu | Fan Yu, Director | |
| ABG Innovation Capital Partners III GP, L.P. | 0.1% | 26,666 | 26,666 | 26,666 | By: ABG Innovation Capital Partners III GP Limited, its general partner, By: /s/ Fan Yu | Fan Yu, Director | |
| Ally Bridge Group Innovation Capital Partners III, L.P. | 0.1% | 26,666 | 26,666 | 26,666 | By: ABG Innovation Capital Partners III GP, L.P., its general partner, By: ABG Innovation Capital Partners III GP Limited, its general partner, By: | Fan Yu, Director | |
| ABG Innovation-SO Limited | 0.1% | 26,666 | 26,666 | 26,666 | By: /s/ Shan-ju Yeh | Shan-ju Yeh, Director | |
| ABG Global Life Science Capital Partners V GP Limited | 4.5% | 2,070,000 | 2,070,000 | 2,070,000 | By: /s/ Shan-ju Yeh | Shan-ju Yeh, Director | |
| ABG Global Life Science Capital Partners V GP, L.P. | 4.5% | 2,070,000 | 2,070,000 | 2,070,000 | By: ABG Global Life Science Capital Partners V GP Limited, its general partner, By: /s/ Shan-ju Yeh | Shan-ju Yeh, Director | |
| Ally Bridge Group Global Life Science Capital Partners V, L.P. | 4.5% | 2,070,000 | 2,070,000 | 2,070,000 | By: ABG Global Life Science Capital Partners V GP, L.P., its general partner, By: ABG Global Life Science Capital Partners V GP Limited, its general | Shan-ju Yeh, Director | |
| ABG-SIV, L.P. | 4.5% | 2,070,000 | 2,070,000 | 2,070,000 | By: ABG Global Life Science Capital Partners V GP, L.P., its general partner, By: ABG Global Life Science Capital Partners V GP Limited, its general | Shan-ju Yeh, Director | |
| ABG V-SIV Limited | 4.5% | 2,070,000 | 2,070,000 | 2,070,000 | By: /s/ Shan-ju Yeh | Shan-ju Yeh, Director | |
| Fan Yu | 6.3% | 2,914,605 | 2,914,605 | 2,914,605 | /s/ Fan Yu | Fan Yu |
CIK / CUSIP context first